Zynerba Pharma (NASDAQ: ZYNE) gains on chatter following the $7.2B acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals. Ladenburg Thalman analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE